Trial Profile
A Multicenter, Single-Arm, 24-Week Study of UB-421 in Combination With Optimized Background Therapy (OBT) Regimen in Patients With Multi-Drug Resistant (MDR) HIV-1 Infection
Status:
Not yet recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Semzuvolimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- 21 Apr 2023 Planned End Date changed from 1 May 2023 to 1 Mar 2024.
- 21 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Mar 2024.
- 21 Apr 2023 Planned initiation date changed from 1 Dec 2021 to 1 Dec 2023.